<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">nogr</journal-id><journal-title-group><journal-title xml:lang="ru">Экспериментальная и клиническая гастроэнтерология</journal-title><trans-title-group xml:lang="en"><trans-title>Experimental and Clinical Gastroenterology</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1682-8658</issn><publisher><publisher-name>«Global Media Technologies»</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.31146/1682-8658-ecg-218-10-133-138</article-id><article-id custom-type="elpub" pub-id-type="custom">nogr-2557</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ПАНКРЕАТОЛОГИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>PANCREATOLOGY</subject></subj-group></article-categories><title-group><article-title>Оценка вклада полиморфизмов гена UGT1A в развитие желчнокаменной болезни</article-title><trans-title-group xml:lang="en"><trans-title>Assessment of the contribution of UGT1A gene polymorphisms to the development of cholelithiasis</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-3606-4068</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Шрайнер</surname><given-names>Е. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Shreiner</surname><given-names>E. V.</given-names></name></name-alternatives><email xlink:type="simple">sch704@icloud.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7308-7280</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Хавкин</surname><given-names>А. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Khavkin</surname><given-names>A. I.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-6688-0640</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Новикова</surname><given-names>М. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Novikova</surname><given-names>M. S.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-6374-1728</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Кох</surname><given-names>Н. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Kokh</surname><given-names>N. V.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1173-7553</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Денисов</surname><given-names>М. Ю.</given-names></name><name name-style="western" xml:lang="en"><surname>Denisov</surname><given-names>M. Yu.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-9048-7710</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Лифшиц</surname><given-names>Г. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Lifshits</surname><given-names>G. I.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Новосибирский государственный университет; Институт химической биологии и фундаментальной медицины СО РА</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Novosibirsk State University; Institute of chemical, Institute of Chemical Biology and Fundamental Medicine of the SB RAS</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>Научно-исследовательский клинический институт детства Министерства здравоохранения Московской области; Белгородский государственный исследовательский университет Министерства науки и высшего образования Российской Федерации</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Research Clinical Institute of Childhood, Ministry of Health of the Moscow Region; Belgorod State Research University</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>Новосибирский государственный университет</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Novosibirsk State University</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2023</year></pub-date><pub-date pub-type="epub"><day>15</day><month>03</month><year>2024</year></pub-date><volume>0</volume><issue>10</issue><fpage>133</fpage><lpage>138</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Шрайнер Е.В., Хавкин А.И., Новикова М.С., Кох Н.В., Денисов М.Ю., Лифшиц Г.И., 2024</copyright-statement><copyright-year>2024</copyright-year><copyright-holder xml:lang="ru">Шрайнер Е.В., Хавкин А.И., Новикова М.С., Кох Н.В., Денисов М.Ю., Лифшиц Г.И.</copyright-holder><copyright-holder xml:lang="en">Shreiner E.V., Khavkin A.I., Novikova M.S., Kokh N.V., Denisov M.Y., Lifshits G.I.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.nogr.org/jour/article/view/2557">https://www.nogr.org/jour/article/view/2557</self-uri><abstract><p>Знание о генетических особенностях пациента позволяет сформировать персонализированный подход при ежегодно возрастающей заболеваемости желчнокаменной болезнью (ЖКБ, холелитиаз), что способствует увеличению вероятности успеха лекарственной терапии. Холелитиаз - это многофакторная патология, немаловажную роль в патогенезе которой имеют генетические факторы. Особый интерес для более ранней профилактики и активного ведения таких пациентов представляет изучение таких генетических факторов. В данной работе произведена оценка вклада полиморфизмов гена UGT1A (rs8175347 ((TA)n), rs2070959 (A&gt;G) и rs10929302 (G&gt;A)) в развитие ЖКБ. Исследование показало, что носительство минорного аллеля локуса rs8175347 гена UGT1A статистически значимо увеличивает вероятность развития холелитиаза в 5,4 раза (CI=1-31; ch²=3,9; p&lt;0,05), rs2070959 на уровне тенденции (RR=2,8; CI=0,8-9; ch²=2,9; p=0,08), rs10929302 не связан с ЖКБ (RR=3,1; CI=0,3-27; ch²=1,1; p=0,2).</p></abstract><trans-abstract xml:lang="en"><p>Iron overload in non-alcoholic fatty liver disease (NAFLD) is a fairly common phenomenon that receives very little attention in clinical practice. However, iron overload, leading to hemosiderosis (deposition of “indigestible” nanodispersed iron oxides in various tissues) significantly aggravates NAFLD, stimulating increased chronic inflammation, insulin resistance and hemosiderosis of other organs. As a result, ferroptosis of hepatocytes occurs (apoptosis caused by iron overload and hemosiderosis), which accelerates the transformation of non-alcoholic steatosis into non-alcoholic steatohepatitis (NASH) and, subsequently, into liver cirrhosis. Iron overload is aggravated by micronutrient deficiencies and pathogenic intestinal microbiota. The paper presents the results of a systematic analysis of this issue, describes the prospects for therapy using micronutrients and human placenta hydrolysates (HPP), which contribute not only to the regeneration of liver tissue, but also to the normalization of iron homeostasis.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>желчнокаменная болезнь</kwd><kwd>уридиндифосфат-глюкуронилтрансфераза</kwd><kwd>персонализированная медицина</kwd></kwd-group><kwd-group xml:lang="en"><kwd>iron overload</kwd><kwd>hemosiderosis</kwd><kwd>fatty liver disease</kwd><kwd>human placenta hydrolysates</kwd><kwd>data mining</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Vítek L., Tiribelli C. Gilbert’s syndrome revisited. J Hepatol. 2023 Oct;79(4):1049-1055. doi: 10.1016/j.jhep.2023.06.004.</mixed-citation><mixed-citation xml:lang="en">Vítek L., Tiribelli C. Gilbert’s syndrome revisited. J Hepatol. 2023 Oct;79(4):1049-1055. doi: 10.1016/j.jhep.2023.06.004.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Frybova B., Drabek J., Lochmannova J., Douda L., Hlava S., Zemkova D. et al. Cholelithiasis and choledocholithiasis in children: risk factors for development. PLoS One. 2018. 13(5): e0196475. doi:10.1371/journal.pone.0196475.</mixed-citation><mixed-citation xml:lang="en">Frybova B., Drabek J., Lochmannova J., Douda L., Hlava S., Zemkova D. et al. Cholelithiasis and choledocholithiasis in children: risk factors for development. PLoS One. 2018. 13(5): e0196475. doi:10.1371/journal.pone.0196475.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Kim J., Cheong H., Park B. et al.Comprehensive variant screening of the UGT gene family. Yonsei Med J. 2014. 55(1): 232-239. doi: 10.3349/ymj.2014.55.1.232.</mixed-citation><mixed-citation xml:lang="en">Kim J., Cheong H., Park B. et al.Comprehensive variant screening of the UGT gene family. Yonsei Med J. 2014. 55(1): 232-239. doi: 10.3349/ymj.2014.55.1.232.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Sidorenko D. V., Nazarov V. D., Volnikova E. G., Kondrasheva E. A., Peshkova N. G., Kovaleva I. S. et al. Dependence of blood biochemical parameters on various genotypes of the UGT1A1 gene associated with Gilbert’s syndrome. Klinicheskaja laboratornaja diagnostika (Russian Clinical Laboratory Diagnostics). 2022. 67(2): 69-75. (in Russ.) doi: 10.51620/0869-2084-2022-67-2-69-75. @@ Сидоренко Д. В., Назаров В. Д., Волникова Е. Г., Кондрашева Е. А., Пешкова Н. Г., Ковалева И. С. и др. Зависимость биохимических показателей крови от различных генотипов гена UGT1A1, ассоциированного с синдромом Жильбера. Клиническая лабораторная диагностика. 2022. Т. 67. № 2. С. 69-75. doi:10.51620/0869-2084-2022-67-2-69-75.</mixed-citation><mixed-citation xml:lang="en">Sidorenko D. V., Nazarov V. D., Volnikova E. G., Kondrasheva E. A., Peshkova N. G., Kovaleva I. S. et al. Dependence of blood biochemical parameters on various genotypes of the UGT1A1 gene associated with Gilbert’s syndrome. Klinicheskaja laboratornaja diagnostika (Russian Clinical Laboratory Diagnostics). 2022. 67(2): 69-75. (in Russ.) doi: 10.51620/0869-2084-2022-67-2-69-75. @@ Сидоренко Д. В., Назаров В. Д., Волникова Е. Г., Кондрашева Е. А., Пешкова Н. Г., Ковалева И. С. и др. Зависимость биохимических показателей крови от различных генотипов гена UGT1A1, ассоциированного с синдромом Жильбера. Клиническая лабораторная диагностика. 2022. Т. 67. № 2. С. 69-75. doi:10.51620/0869-2084-2022-67-2-69-75.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Barbarino J. M., Haidar C. E., Klein T. E., Altman R. B. PharmGKB summary: very important pharmacogene information for UGT1A1. Pharmacogenet Genomics. 2014 Mar;24(3):177-83. doi: 10.1097/FPC.0000000000000024.</mixed-citation><mixed-citation xml:lang="en">Barbarino J. M., Haidar C. E., Klein T. E., Altman R. B. PharmGKB summary: very important pharmacogene information for UGT1A1. Pharmacogenet Genomics. 2014 Mar;24(3):177-83. doi: 10.1097/FPC.0000000000000024.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Steventon G. Uridine diphosphate glucuronosyltransferase 1A1. Xenobiotica. 2020. 50(1): 64-76. doi:10.1080/00498254.2019.1617910.</mixed-citation><mixed-citation xml:lang="en">Steventon G. Uridine diphosphate glucuronosyltransferase 1A1. Xenobiotica. 2020. 50(1): 64-76. doi:10.1080/00498254.2019.1617910.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Deming S. L., Zheng W., Xu W. H., Cai Q., Ruan Z., Xiang Y. B., Shu X. O. UGT1A1 genetic polymorphisms, endogenous estrogen exposure, soy food intake, and endometrial cancer risk. Cancer Epidemiol Biomarkers Prev. 2008 Mar;17(3):563-70. doi: 10.1158/1055-9965.EPI-07-0752.</mixed-citation><mixed-citation xml:lang="en">Deming S. L., Zheng W., Xu W. H., Cai Q., Ruan Z., Xiang Y. B., Shu X. O. UGT1A1 genetic polymorphisms, endogenous estrogen exposure, soy food intake, and endometrial cancer risk. Cancer Epidemiol Biomarkers Prev. 2008 Mar;17(3):563-70. doi: 10.1158/1055-9965.EPI-07-0752.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Agrawal V., Tiwari A., Sharma D., Agrawal R. Etiology-Based Decision-Making Protocol for Pediatric Cholelithiasis. Indian Pediatr. 2021. 58(8): 729-732.</mixed-citation><mixed-citation xml:lang="en">Agrawal V., Tiwari A., Sharma D., Agrawal R. Etiology-Based Decision-Making Protocol for Pediatric Cholelithiasis. Indian Pediatr. 2021. 58(8): 729-732.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Kurilovich S. A., Nemtsova E. G., Kruchinina M. V., Maximov V. N. Features of gilbert’s syndrome in patients with different genotypes UGT1A1. Experimental and Clinical Gastroenterology. 2016;(9):32-37. (In Russ.)</mixed-citation><mixed-citation xml:lang="en">Kurilovich S. A., Nemtsova E. G., Kruchinina M. V., Maximov V. N. Features of gilbert’s syndrome in patients with different genotypes UGT1A1. Experimental and Clinical Gastroenterology. 2016;(9):32-37. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Sandra L. Deming, Wei Zheng, Wang-Hong Xu, Qiuyin Cai, Zhixian Ruan, Yong-Bing Xiang, Xiao-Ou Shu. UGT1A1 Genetic Polymorphisms, Endogenous Estrogen Exposure, Soy Food Intake, and Endometrial Cancer Risk. Cancer Epidemiol Biomarkers Prev 1 March 2008; 17 (3): 563-570. (in Russ.) doi: 10.1158/1055-9965.EPI-07-0752.@@ Новикова М. С., Шрайнер Е. В., Лифщиц Г. И., Кох Н. В., Хавкин А. И. Взаимосвязь желчнокаменной болезни и метаболического синдрома: роль генетических факторов. Экспериментальная и клиническая гастроэнтерология. 2022;(7):204-210. doi: 10.31146/1682-8658-ecg-203-7-204-210</mixed-citation><mixed-citation xml:lang="en">Sandra L. Deming, Wei Zheng, Wang-Hong Xu, Qiuyin Cai, Zhixian Ruan, Yong-Bing Xiang, Xiao-Ou Shu. UGT1A1 Genetic Polymorphisms, Endogenous Estrogen Exposure, Soy Food Intake, and Endometrial Cancer Risk. Cancer Epidemiol Biomarkers Prev 1 March 2008; 17 (3): 563-570. (in Russ.) doi: 10.1158/1055-9965.EPI-07-0752.@@ Новикова М. С., Шрайнер Е. В., Лифщиц Г. И., Кох Н. В., Хавкин А. И. Взаимосвязь желчнокаменной болезни и метаболического синдрома: роль генетических факторов. Экспериментальная и клиническая гастроэнтерология. 2022;(7):204-210. doi: 10.31146/1682-8658-ecg-203-7-204-210</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Du Z, Xu H, Zhao P, Wang J, Xu Q, Liu M. Influence of UGT2B7 and UGT1A6 polymorphisms on plasma concentration to dose ratio of valproic acid in Chinese epileptic children. Xenobiotica. 2021 Jul;51(7):859-864. doi: 10.1080/00498254.2021.1931554.</mixed-citation><mixed-citation xml:lang="en">Du Z, Xu H, Zhao P, Wang J, Xu Q, Liu M. Influence of UGT2B7 and UGT1A6 polymorphisms on plasma concentration to dose ratio of valproic acid in Chinese epileptic children. Xenobiotica. 2021 Jul;51(7):859-864. doi: 10.1080/00498254.2021.1931554.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Li M., Seiser E. L., Baldwin R. M., Ramirez J., Ratain M. J., Innocenti F., Kroetz D. L. ABC transporter polymorphisms are associated with irinotecan pharmacokinetics and neutropenia. Pharmacogenomics J. 2018 Jan;18(1):35-42. doi: 10.1038/tpj.2016.75.</mixed-citation><mixed-citation xml:lang="en">Li M., Seiser E. L., Baldwin R. M., Ramirez J., Ratain M. J., Innocenti F., Kroetz D. L. ABC transporter polymorphisms are associated with irinotecan pharmacokinetics and neutropenia. Pharmacogenomics J. 2018 Jan;18(1):35-42. doi: 10.1038/tpj.2016.75.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Ferraldeschi R., Minchell L. J., Roberts S. A. et al. UGT1A1*28 genotype predicts gastrointestinal toxicity in patients treated with intermediate-dose irinotecan. Pharmacogenomics. 2009 May;10(5):733-9. doi: 10.2217/pgs.09.20.</mixed-citation><mixed-citation xml:lang="en">Ferraldeschi R., Minchell L. J., Roberts S. A. et al. UGT1A1*28 genotype predicts gastrointestinal toxicity in patients treated with intermediate-dose irinotecan. Pharmacogenomics. 2009 May;10(5):733-9. doi: 10.2217/pgs.09.20.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Bhatt D. K., Mehrotra A., Gaedigk A. et al. Age- and Genotype-Dependent Variability in the Protein Abundance and Activity of Six Major Uridine Diphosphate-Glucuronosyltransferases in Human Liver. Clin Pharmacol Ther. 2019 Jan;105(1):131-141. doi: 10.1002/cpt.1109.</mixed-citation><mixed-citation xml:lang="en">Bhatt D. K., Mehrotra A., Gaedigk A. et al. Age- and Genotype-Dependent Variability in the Protein Abundance and Activity of Six Major Uridine Diphosphate-Glucuronosyltransferases in Human Liver. Clin Pharmacol Ther. 2019 Jan;105(1):131-141. doi: 10.1002/cpt.1109.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Ufimtseva I. V., Pirogova I.Yu., Sinitsyn S. P., Yakovleva S. V. Features of the course of gallstone disease in comorbid patients with non-alcoholic fatty liver disease. Experimental and Clinical Gastroenterology. 2022;(7):103-109. (in Russ.) doi: 10.31146/1682-8658-ecg-203-7-103-109.@@ Уфимцева И. В., Пирогова И. Ю., Синицын С. П., Яковлева С. В. Особенности течения ЖКБ у пациентов с неалкогольной жировой болезнью печени. Экспериментальная и клиническая гастроэнтерология. 2022;(7):103-109. doi: 10.31146/1682-8658-ecg-203-7-103-109.</mixed-citation><mixed-citation xml:lang="en">Ufimtseva I. V., Pirogova I.Yu., Sinitsyn S. P., Yakovleva S. V. Features of the course of gallstone disease in comorbid patients with non-alcoholic fatty liver disease. Experimental and Clinical Gastroenterology. 2022;(7):103-109. (in Russ.) doi: 10.31146/1682-8658-ecg-203-7-103-109.@@ Уфимцева И. В., Пирогова И. Ю., Синицын С. П., Яковлева С. В. Особенности течения ЖКБ у пациентов с неалкогольной жировой болезнью печени. Экспериментальная и клиническая гастроэнтерология. 2022;(7):103-109. doi: 10.31146/1682-8658-ecg-203-7-103-109.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Xiang G. Q., Sun F. R., Wang B. Y. [Gilbert’s syndrome: hyperbilirubinemia enemy or friend]. Zhonghua Gan Zang Bing Za Zhi. 2021 Oct 20;29(10):1024-1027. Chinese. doi: 10.3760/cma.j.cn501113-20200212-00041.</mixed-citation><mixed-citation xml:lang="en">Xiang G. Q., Sun F. R., Wang B. Y. [Gilbert’s syndrome: hyperbilirubinemia enemy or friend]. Zhonghua Gan Zang Bing Za Zhi. 2021 Oct 20;29(10):1024-1027. Chinese. doi: 10.3760/cma.j.cn501113-20200212-00041.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Vitek L., Jirsa M., Brodanova M. et al. Gilbert syndrome and ischemic heart disease: a protective effect of elevated bilirubin levels. Atherosclerosis. 2002 Feb;160(2):449-56. doi: 10.1016/s0021-9150(01)00601-3.</mixed-citation><mixed-citation xml:lang="en">Vitek L., Jirsa M., Brodanova M. et al. Gilbert syndrome and ischemic heart disease: a protective effect of elevated bilirubin levels. Atherosclerosis. 2002 Feb;160(2):449-56. doi: 10.1016/s0021-9150(01)00601-3.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Ivanov A., Semenova E. Gilbert’s Syndrome, Bilirubin Level and UGT1A1*28 Genotype in Men of North-West Region of Russia. J Clin Exp Hepatol. 2021 Nov-Dec;11(6):691-699. doi: 10.1016/j.jceh.2021.01.006.</mixed-citation><mixed-citation xml:lang="en">Ivanov A., Semenova E. Gilbert’s Syndrome, Bilirubin Level and UGT1A1*28 Genotype in Men of North-West Region of Russia. J Clin Exp Hepatol. 2021 Nov-Dec;11(6):691-699. doi: 10.1016/j.jceh.2021.01.006.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Passon R.G, Howard T.A, Zimmerman S.A, Schultz W.H, Ware R. E. Influence of bilirubin uridine diphosphate-glucuronosyltransferase 1A promoter polymorphisms on serum bilirubin levels and cholelithiasis in children with sickle cell anemia. J Pediatr Hematol Oncol. 2001 Oct;23(7):448-51. doi: 10.1097/00043426-200110000-00011.</mixed-citation><mixed-citation xml:lang="en">Passon R.G, Howard T.A, Zimmerman S.A, Schultz W.H, Ware R. E. Influence of bilirubin uridine diphosphate-glucuronosyltransferase 1A promoter polymorphisms on serum bilirubin levels and cholelithiasis in children with sickle cell anemia. J Pediatr Hematol Oncol. 2001 Oct;23(7):448-51. doi: 10.1097/00043426-200110000-00011.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
